This page contains guidance issued by the GMMMG High Cost Drugs Subgroup. If you are an NHS healthcare professional working within the GM region and wish to submit information for consideration by the group please contact the professional secretary of the group via email

Document Title Issue Date Review Date Status
GMMMG PBR Ex Devices 2020-21 20200605 Jun 2020 20210405 Apr 2021
GMMMG PBR Ex Drugs 2020-21 20200605 Jun 2020 20210405 Apr 2021
GMMMG PBR Exclusions supporting information 20-21 20201005 Oct 2020 20211005 Oct 2021
Enabled Blueteq List 20210905 Sep 2021 updated monthly
Management of CCG-commissioned high cost drugs in the context of the COVID-19 pandemic 20200405 Apr 2020
Free of charge (FOC) medicines schemes 20200105 Jan 2020 20220105 Jan 2022
Position statement: Funding of high cost drugs when patients transition from children or adolescent services to adult services 20171005 Oct 2017 To be reviewed if national or GMMMG guidance changes
Sequential use of high cost drugs statement 20220605 Jun 2022
Commissioning framework for biologic medicines: defining best value 20180605 Jun 2018 To be reviewed if national or GMMMG guidance changes
Implementation and principles of a Greater Manchester biosimilar gainshare agreement 20170705 Jul 2017 To be reviewed if national or GMMMG guidance changes
Prescribing of high cost biosimilar biological medicines 20160705 Jul 2016 To be reviewed if national or GMMMG guidance changes
Position statement for using biologic therapies to treat adult patients with Juvenile Idiopathic Arthritis (JIA) 20171005 Oct 2017 To be reviewed if national or GMMMG guidance changes
Best Value Adalimumab: decision and uptake recommendation 20181205 Dec 2018
Botulinum toxin guidance 20200105 Jan 2020 20220105 Jan 2022
Rituximab Biosimilar Uptake Recommendation 20170605 Jun 2017 To be reviewed if national or GMMMG guidance changes
Teriparatide biosimilar uptake recommendation 20191105 Nov 2019 To be reviewed if national or GMMMG guidance changes